Evidence map›Paper›PMID 37101541›Full record

ArticleComplex psychiatry

Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress Models.

Yashika Bansal, Corey Fee, Keith A Misquitta, Sierra A Codeluppi, Etienne Sibille, Robert M Berman, Vladimir Coric, Gerard Sanacora, Mounira Banasr

Open access · hybridAbstract read
In one paragraph

Article in Complex psychiatry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Yashika BansalCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Corey FeeCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Keith A MisquittaCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Sierra A CodeluppiCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Etienne SibilleCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Robert M BermanBiohaven Pharmaceuticals, New Haven, CT, USA.
Vladimir CoricBiohaven Pharmaceuticals, New Haven, CT, USA.
Gerard SanacoraDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Mounira BanasrCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Centre for Addiction and Mental Health · CABiohaven Pharmaceuticals (United States) · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic stress-related illnesses such as major depressive disorder and post-traumatic stress disorder share symptomatology, including anxiety, anhedonia, and helplessness. Across disorders, neurotoxic dysregulated glutamate (Glu) signaling may underlie symptom emergence. Current first-line antidepressant drugs, which do not directly target Glu signaling, fail to provide adequate benefit for many patients and are associated with high relapse rates. Riluzole modulates glutamatergic neurotransmission by increasing metabolic cycling and modulating signal transduction. Clinical studies exploring riluzole's efficacy in stress-related disorders have provided varied results. However, the utility of riluzole for treating specific symptom dimensions or as a prophylactic treatment has not been comprehensively assessed. Methods: We investigated whether chronic prophylactic riluzole (∼12-15 mg/kg/day p.o.) could prevent the emergence of behavioral deficits induced by unpredictable chronic mild stress (UCMS) in mice. We assessed (i) anxiety-like behavior using the elevated-plus maze, open-field test, and novelty-suppressed feeding, (ii) mixed anxiety/anhedonia-like behavior in the novelty-induced hypophagia test, and (iii) anhedonia-like behavior using the sucrose consumption test. Z-scoring summarized changes across tests measuring similar dimensions. In a separate learned helplessness (LH) cohort, we investigated whether chronic prophylactic riluzole treatment could block the development of helplessness-like behavior. Results: UCMS induced an elevation in anhedonia-like behavior and overall behavioral emotionality that was blocked by prophylactic riluzole. In the LH cohort, prophylactic riluzole blocked the development of helplessness-like behavior. Discussion/Conclusion: This study supports the utility of riluzole as a prophylactic medication for preventing anhedonia and helplessness symptoms associated with stress-related disorders.

Indexed as

AntidepressantsChronic stressDepressionProphylactic riluzoleRiluzole

Identifiers

PMID37101541
PMCPMC10123365
OpenAlexW4319067891

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.